These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7704494)

  • 41. Establishment of the standard regimen for non-small-cell lung cancer in Japan.
    Masuda N
    Oncology (Williston Park); 2001 Jan; 15(1 Suppl 1):13-8. PubMed ID: 11221016
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Chemotherapy of advanced non-small cell bronchial cancer with mitomycin C/ifosfamide versus mitomycin C/vindesine versus cisplatin/etoposide--a prospective randomized study].
    Gatzemeier U; Heckmayr M; Hossfeld DK; Kaukel E; Koschel G; Neuhauss R
    Pneumologie; 1990 Feb; 44 Suppl 1():258-60. PubMed ID: 2164194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extensive non-small cell lung cancer treated with mitomycin, cisplatin, and vindesine (MiPE): a Southwest Oncology Group Study.
    Miller TP; Vance RB; Ahmann FR; Rodney SR
    Cancer Treat Rep; 1986 Sep; 70(9):1101-4. PubMed ID: 3527409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Chemotherapy of non-small cell bronchial cancer with mitomycin C, vindesine and cisplatin. Results of a phase II study].
    Koschel G; Kaukel E; Hain E
    Onkologie; 1987 Apr; 10(2):90-5. PubMed ID: 3035447
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer.
    Recchia F; Sica G; De Filippis S; Rea S; Frati L
    Anticancer Res; 1997; 17(5B):3761-5. PubMed ID: 9427776
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Mitomycin, vindesine and cisplatin combination therapy in the treatment of advanced non-small cell lung cancer: a report of 108 cases].
    Zhang X; Sun Y; Feng F
    Zhonghua Zhong Liu Za Zhi; 1999 May; 21(3):220-3. PubMed ID: 11776842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study.
    Vermorken JB; Zanetta G; De Oliveira CF; van der Burg ME; Lacave AJ; Teodorovic I; Boes GH; Colombo N
    Ann Oncol; 2001 Jul; 12(7):967-74. PubMed ID: 11521804
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Moderate dose-intensive chemotherapy for patients with non-small cell lung cancer: randomized trial, can it improve survival of patients with good performance status?
    Masutani M; Tsujino I; Fujie T; Yamaguchi M; Miyagi K; Yano T; Takahashi N; Koya Y; Horie T
    Oncol Rep; 1999; 6(5):1045-50. PubMed ID: 10425301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Cisplatin, doxorubicin and vindesine in the treatment of advanced non-small cell lung cancer].
    Akiyama J; Sato A; Honda K; Chida K; Watanabe T; Okano H; Okano A; Taniguchi M; Genma H; Aoki H
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):419-24. PubMed ID: 1848420
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of cisplatin plus vindesine with cisplatin plus mitomycin C for treatment of advanced non-small-cell lung cancer. The Eastern Shikoku Lung Cancer Chemotherapy Group.
    Shimizu E; Ogura T; Sone S; Nakayama T; Doi H; Takishita Y; Bando H; Kobayashi M; Kimura K; Sasaki H
    Oncology; 1993; 50(1):5-9. PubMed ID: 8380634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients.
    Le Chevalier T; Brisgand D; Douillard JY; Pujol JL; Alberola V; Monnier A; Riviere A; Lianes P; Chomy P; Cigolari S
    J Clin Oncol; 1994 Feb; 12(2):360-7. PubMed ID: 8113844
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug delivery analysis of the Canadian multicenter trial in non-small-cell lung cancer.
    Murray N; Coppin C; Coldman A; Pater J; Rapp E
    J Clin Oncol; 1994 Nov; 12(11):2333-9. PubMed ID: 7964949
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegaful) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for lung cancer surgery (WJSG).
    Wada H; Miyahara R; Tanaka F; Hitomi S
    Eur J Cardiothorac Surg; 1999 Apr; 15(4):438-43. PubMed ID: 10371118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer.
    Shinkai T; Saijo N; Tominaga K; Eguchi K; Shimizu E; Sasaki Y; Fujita J; Futami H
    Cancer Treat Rep; 1985 Sep; 69(9):945-51. PubMed ID: 2992785
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study.
    Jelić S; Mitrović L; Radosavljević D; Elezar E; Babović N; Kovcin V; Tomasević Z; Kovacević S; Gavrilović D; Radulović S
    Lung Cancer; 2001 Oct; 34(1):1-13. PubMed ID: 11557107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interleukin-2, cisplatin, and 5-fluorouracil for patients with non-small cell lung and head/neck carcinomas.
    Valone FH; Gandara DR; Deisseroth AB; Perez EA; Rayner A; Aronson FR; Luce J; Paradise C
    J Immunother (1991); 1991 Jun; 10(3):207-13. PubMed ID: 1651106
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of two chemotherapeutic regimens--mitomycin + vindesine + cisplatin (MVP) vs. mitomycin + ifosfamide + cisplatin (MIP)--in advanced non-small-cell lung cancer. ONCOPAZ Cooperative Group.
    González Barón M; Feliu J; Espinosa E; García Girón C; Blanco E; Garrido P; Colmenarejo A; Ordóñez A; Moyano A; de la Gándara I
    Ann Oncol; 1994 Apr; 5(4):323-7. PubMed ID: 8075028
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of mitomycin C, etoposide and vindesine in metastatic stage IV non-small-cell lung cancer.
    Gridelli C; Pepe R; Palmeri S; Iacobelli S; Gentile M; Gebbia V; Garufi C; Airoma G; Palmieri G; Russo A
    Cancer Chemother Pharmacol; 1991; 28(5):405-7. PubMed ID: 1655301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized phase II trial comparing two chemotherapy combinations for non-small cell lung cancer. Mitomycin, ifosfamide, and cisplatin versus vindesine, ifosfamide, and cisplatin.
    González Barón M; Artal A; Garrido P; García Girón C; Ordóñez A; Feliu J; Berrocal A; Barón JM
    Am J Clin Oncol; 1993 Aug; 16(4):310-4. PubMed ID: 8392287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase III randomized trial of cisplatin plus vindesine versus cisplatin plus vindesine plus mitomycin C versus cisplatin plus vindesine plus ifosfamide for advanced non-small-cell lung cancer.
    Masutani M; Akusawa H; Kadota A; Ohchi Y; Takahashi N; Tanigawa S; Koya Y; Horie T
    Respirology; 1996 Mar; 1(1):49-54. PubMed ID: 9432405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.